drugset / Trial / NCT00430027

Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma

NCT00430027

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this pilot study is to determine whether neoadjuvant capecitabine/oxaliplatin/cetuximab and external beam radiation therapy followed by surgical resection \[and then followed by post operative adjuvant capecitabine, oxaliplatin and cetuximab\] is feasible and tolerable.

Timeline

Start
2006-11
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 825 mg/m2
Subject Cetuximab Monoclonal antibody 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous